Li Auto’s Q1 Performance: 97% Topline Growth, Higher Deliveries, Robust Q2 Outlook

Li Auto Inc (NASDAQ:LI) reported first-quarter FY23 sales growth of 96.5% year-on-year to $2.736 billion, slightly missing the consensus of…
  • Li Auto Inc (NASDAQ:LI) reported first-quarter FY23 sales growth of 96.5% year-on-year to $2.736 billion, slightly missing the consensus of $2.750 billion.
  • Adjusted earnings per ADS of $0.200 beat the consensus of $0.010.
  • Vehicle sales increased 96.9% to $2.67 billion, mainly attributable to the increase in vehicle deliveries and the higher average selling price contributed by the Li L series.
  • Total vehicle deliveries were 52,584 units in Q1, a 65.8% year-on-year increase.
  • Vehicle margin fell 260 basis points Y/Y to 19.8%.
  • Gross profit increased 77% Y/Y to $557.7 million, with the margin contracting 220 basis points to 20.4%.
  • Non-GAAP income from operations was $128.9 million.
  • The company held cash and equivalents of $9.46 billion. Cash provided by operating activities was $1.13 billion, up 324.3% Y/Y.
  • As of March 31, 2023, the company had 299 retail stores covering 123 cities, as well as 318 servicing centers and Li Auto-authorized body and paint shops operating in 223 cities.
  • In April 2023, the company delivered 25,681 vehicles, representing an increase of 516.3% from April 2022.
  • Outlook: Li Auto sees Q2 FY23 revenue of $3.53 billion – $3.77 billion (consensus $3.29 billion), representing an increase of 177.4% – 196.1% Y/Y.
  • LI expects Q2 vehicle deliveries of 76,000 – 81,000, representing an increase of 164.9% – 182.4% Y/Y.
  • Price Action: LI shares traded higher by 5.93% at $26.24 in premarket on the last check Wednesday.
  • Photo via Wikimedia Commons
Total
0
Shares
Related Posts
Read More

Galapagos Concludes Strategic Evaluation And Signs Letter Of Intent To Transfer Jyseleca Business To Alfasigma; Co Will Receive A €50M Upfront, Potential Milestone Payments Totaling €120M And Mid-single To Mid-double-digit Royalties On European Sales

Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicinesAims to preserve the Jyseleca® (filgotinib) business and a

GLPG